StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report published on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
TTNP opened at $5.66 on Friday. Titan Pharmaceuticals has a 52-week low of $4.24 and a 52-week high of $14.80. The firm’s 50-day moving average price is $5.93 and its 200-day moving average price is $6.43.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- ETF Screener: Uses and Step-by-Step Guide
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.